PGEN
Precigen Inc

8,919
Mkt Cap
$1.58B
Volume
6.03M
52W High
$5.47
52W Low
$1.11
PE Ratio
-3.13
PGEN Fundamentals
Price
$4.38
Prev Close
$4.51
Open
$4.45
50D MA
$4.39
Beta
1.84
Avg. Volume
3.79M
EPS (Annual)
-$0.4715
P/B
37.02
Rev/Employee
$27,447.55
$235.66
Loading...
Loading...
News
all
press releases
Precigen (NASDAQ:PGEN) Shares Down 6% - What's Next?
Precigen (NASDAQ:PGEN) Trading Down 6% - Should You Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Precigen (NASDAQ:PGEN) Trading 5.2% Higher - Still a Buy?
Precigen (NASDAQ:PGEN) Stock Price Up 5.2% - Still a Buy...
MarketBeat·4d ago
News Placeholder
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis...
PR Newswire·1mo ago
News Placeholder
Precigen, Inc. (NASDAQ:PGEN) Sees Large Growth in Short Interest
Precigen, Inc. (NASDAQ:PGEN - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 35,580,646 shares, a...
MarketBeat·1mo ago
News Placeholder
Precigen (NASDAQ:PGEN) Shares Gap Up - What's Next?
Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Rating of "Moderate Buy" by Analysts
Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat Ratings reports. One...
MarketBeat·1mo ago
News Placeholder
Precigen (NASDAQ:PGEN) Trading Down 7.5% - What's Next?
Precigen (NASDAQ:PGEN) Shares Down 7.5% - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference Precigen Showcases...
PR Newswire·1mo ago
News Placeholder
Iridian Asset Management LLC CT Sells 611,716 Shares of Precigen, Inc. $PGEN
Iridian Asset Management LLC CT cut its stake in Precigen, Inc. (NASDAQ:PGEN - Free Report) by 14.3% in the third quarter, according to the company in its most recent filing with the Securities and...
MarketBeat·1mo ago
News Placeholder
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire GERMANTOWN, Md., Jan. 5, 2026 GERMANTOWN...
PR Newswire·2mo ago
<
1
2
...
>

Latest PGEN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.